What is Neurocrine Biosciences Inc's earnings per share (EPS)?

Neurocrine Biosciences Inc (NBIX) reported diluted earnings per share of $4.67 for fiscal year 2025. This represents a 41.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Neurocrine Biosciences Inc Financials

NBIX

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Neurocrine Biosciences Inc (NBIX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 72/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Neurocrine Biosciences Inc has an operating margin of 21.6%, meaning the company retains $22 of operating profit per $100 of revenue. This strong profitability earns a score of 70/100, reflecting efficient cost management and pricing power. This is down from 24.2% the prior year.

Growth

Neurocrine Biosciences Inc's revenue surged 21.4% year-over-year to $2.9B, reflecting rapid business expansion. This strong growth earns a score of 69/100.

Leverage

Neurocrine Biosciences Inc carries a low D/E ratio of 0.42, meaning only $0.42 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 93/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 3.39, Neurocrine Biosciences Inc holds $3.39 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 66/100.

Cash Flow

Neurocrine Biosciences Inc converts 26.2% of revenue into free cash flow ($748.7M). This strong cash generation earns a score of 90/100.

Returns

Neurocrine Biosciences Inc's ROE of 14.7% shows moderate profitability relative to equity, earning a score of 44/100. This is up from 13.2% the prior year.

Altman Z-Score Safe

7.45

Neurocrine Biosciences Inc scores 7.45, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($13.3B) relative to total liabilities ($1.4B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Piotroski F-Score Neutral

4/9

Neurocrine Biosciences Inc passes 4 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality Cash-Backed

1.64x

For every $1 of reported earnings, Neurocrine Biosciences Inc generates $1.64 in operating cash flow ($782.7M OCF vs $478.6M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$2.9B

YoY+21.4%

5Y CAGR+22.3%

10Y CAGR+64.5%

Neurocrine Biosciences Inc generated $2.9B in revenue in fiscal year 2025. This represents an increase of 21.4% from the prior year.

EBITDA

$649.2M

YoY+8.6%

5Y CAGR+30.5%

Neurocrine Biosciences Inc's EBITDA was $649.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 8.6% from the prior year.

Net Income

$478.6M

YoY+40.2%

5Y CAGR+3.3%

Neurocrine Biosciences Inc reported $478.6M in net income in fiscal year 2025. This represents an increase of 40.2% from the prior year.

EPS (Diluted)

$4.67

YoY+41.9%

5Y CAGR+2.3%

Neurocrine Biosciences Inc earned $4.67 per diluted share (EPS) in fiscal year 2025. This represents an increase of 41.9% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$748.7M

YoY+34.4%

5Y CAGR+28.0%

Neurocrine Biosciences Inc generated $748.7M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 34.4% from the prior year.

Cash & Debt

$713.0M

YoY+206.0%

5Y CAGR+30.7%

10Y CAGR+25.4%

Neurocrine Biosciences Inc held $713.0M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

100M

YoY+0.7%

5Y CAGR+1.3%

10Y CAGR+1.5%

Neurocrine Biosciences Inc had 100M shares outstanding in fiscal year 2025. This represents an increase of 0.7% from the prior year.

Margins & Returns

Gross Margin

98.2%

YoY-0.4pp

5Y CAGR-0.8pp

10Y CAGR-1.8pp

Neurocrine Biosciences Inc's gross margin was 98.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.4 percentage points from the prior year.

Operating Margin

21.6%

YoY-2.6pp

5Y CAGR+6.1pp

10Y CAGR+498.2pp

Neurocrine Biosciences Inc's operating margin was 21.6% in fiscal year 2025, reflecting core business profitability. This is down 2.6 percentage points from the prior year.

Net Margin

16.7%

YoY+2.2pp

5Y CAGR-22.2pp

10Y CAGR+466.6pp

Neurocrine Biosciences Inc's net profit margin was 16.7% in fiscal year 2025, showing the share of revenue converted to profit. This is up 2.2 percentage points from the prior year.

Return on Equity

14.7%

YoY+1.5pp

5Y CAGR-21.5pp

10Y CAGR+35.7pp

Neurocrine Biosciences Inc's ROE was 14.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 1.5 percentage points from the prior year.

Capital Allocation

R&D Spending

$1.0B

YoY+38.9%

5Y CAGR+29.9%

10Y CAGR+28.7%

Neurocrine Biosciences Inc invested $1.0B in research and development in fiscal year 2025. This represents an increase of 38.9% from the prior year.

Share Buybacks

$167.7M

YoY-44.1%

Neurocrine Biosciences Inc spent $167.7M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 44.1% from the prior year.

Capital Expenditures

$34.0M

YoY-11.0%

5Y CAGR+25.5%

10Y CAGR+33.2%

Neurocrine Biosciences Inc invested $34.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 11.0% from the prior year.

NBIX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$2.9B+21.4%	$2.4B+24.8%	$1.9B+26.8%	$1.5B+31.3%	$1.1B+8.4%	$1.0B
Cost of Revenue	$52.1M+53.2%	$34.0M-14.4%	$39.7M+71.1%	$23.2M+62.2%	$14.3M+41.6%	$10.1M
Gross Profit	$2.8B+21.0%	$2.3B+25.7%	$1.8B+26.1%	$1.5B+30.9%	$1.1B+8.1%	$1.0B
R&D Expenses	$1.0B+38.9%	$731.1M+29.4%	$565.0M+21.8%	$463.8M+41.4%	$328.1M+19.3%	$275.0M
SG&A Expenses	$1.2B+14.8%	$1.0B+13.5%	$887.6M+17.9%	$752.7M+29.0%	$583.3M+34.6%	$433.3M
Operating Income	$619.1M+8.5%	$570.5M+127.4%	$250.9M+0.8%	$249.0M+142.9%	$102.5M-37.1%	$163.0M
Interest Expense	N/A	N/A	$4.6M-35.2%	$7.1M-72.5%	$25.8M-21.3%	$32.8M
Income Tax	$226.8M+56.7%	$144.7M+75.6%	$82.4M+38.7%	$59.4M+403.4%	$11.8M+103.9%	-$300.6M
Net Income	$478.6M+40.2%	$341.3M+36.7%	$249.7M+61.6%	$154.5M+72.4%	$89.6M-78.0%	$407.3M
EPS (Diluted)	$4.67+41.9%	$3.29+33.2%	$2.47+58.3%	$1.56+69.6%	$0.92-77.9%	$4.16

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$805.5M+1.3%	$794.9M+15.6%	$687.5M+20.1%	$572.6M-8.8%	$627.7M+0.9%	$622.1M+5.4%	$590.2M+14.5%	$515.3M
Cost of Revenue	$17.6M+25.7%	$14.0M+23.9%	$11.3M+22.8%	$9.2M-1.1%	$9.3M+16.3%	$8.0M-13.0%	$9.2M+22.7%	$7.5M
Gross Profit	$787.9M+0.9%	$780.9M+15.5%	$676.2M+20.0%	$563.4M-8.9%	$618.4M+0.7%	$614.1M+5.7%	$581.0M+14.4%	$507.8M
R&D Expenses	$258.2M+3.3%	$250.0M+2.3%	$244.3M-7.2%	$263.2M+41.8%	$185.6M-4.8%	$195.0M+2.0%	$191.1M+19.9%	$159.4M
SG&A Expenses	$301.8M+3.5%	$291.6M+1.9%	$286.3M+3.5%	$276.5M-3.9%	$287.8M+22.8%	$234.3M-3.2%	$242.0M-0.5%	$243.1M
Operating Income	$210.9M-11.8%	$239.0M+64.1%	$145.6M+516.9%	$23.6M-83.4%	$142.0M-22.7%	$183.8M+26.4%	$145.4M+46.4%	$99.3M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$1.1M
Income Tax	$85.7M+4.1%	$82.3M+58.3%	$52.0M+664.7%	$6.8M-88.6%	$59.5M-1.7%	$60.5M+80.1%	$33.6M+477.5%	-$8.9M
Net Income	$153.7M-26.6%	$209.5M+94.9%	$107.5M+1260.8%	$7.9M-92.3%	$103.1M-20.6%	$129.8M+99.7%	$65.0M+49.8%	$43.4M
EPS (Diluted)	N/A	$2.04+92.5%	$1.06+1225.0%	$0.08	N/A	$1.24+96.8%	$0.63+50.0%	$0.42

NBIX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$4.6B+24.5%	$3.7B+14.4%	$3.3B+37.3%	$2.4B+14.3%	$2.1B+19.5%	$1.7B
Current Assets	$2.5B+46.3%	$1.7B+7.3%	$1.6B+10.6%	$1.5B+49.4%	$972.8M-4.3%	$1.0B
Cash & Equivalents	$713.0M+206.0%	$233.0M-7.2%	$251.1M-4.5%	$262.9M-22.9%	$340.8M+82.1%	$187.1M
Inventory	$69.0M+20.2%	$57.4M+49.9%	$38.3M+9.1%	$35.1M+15.1%	$30.5M+8.9%	$28.0M
Accounts Receivable	$686.8M+43.4%	$479.1M+9.1%	$439.3M+25.5%	$350.0M+88.7%	$185.5M+18.1%	$157.1M
Goodwill	N/A	$5.7M-1.7%	$5.8M+7.4%	$5.4M	$0	N/A
Total Liabilities	$1.4B+22.1%	$1.1B+10.8%	$1.0B+54.2%	$660.9M-5.4%	$698.5M+14.8%	$608.5M
Current Liabilities	$743.4M+46.4%	$507.7M-22.5%	$654.8M+21.8%	$537.7M+118.8%	$245.8M+31.8%	$186.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$3.3B+25.6%	$2.6B+16.0%	$2.2B+30.7%	$1.7B+24.3%	$1.4B+22.0%	$1.1B
Retained Earnings	$447.7M+1433.2%	$29.2M+118.6%	-$157.1M+61.4%	-$406.8M+36.0%	-$635.8M+12.4%	-$725.4M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$4.6B+8.6%	$4.3B+9.7%	$3.9B+5.5%	$3.7B-0.8%	$3.7B+5.2%	$3.5B+7.0%	$3.3B-4.8%	$3.5B
Current Assets	$2.5B+16.9%	$2.2B+23.4%	$1.7B+6.8%	$1.6B-5.0%	$1.7B-8.1%	$1.9B+12.4%	$1.7B-7.2%	$1.8B
Cash & Equivalents	$713.0M+109.6%	$340.2M+28.9%	$264.0M+36.0%	$194.1M-16.7%	$233.0M-33.3%	$349.1M+149.9%	$139.7M-64.7%	$396.3M
Inventory	$69.0M-0.4%	$69.3M+21.8%	$56.9M-3.7%	$59.1M+3.0%	$57.4M+25.3%	$45.8M+7.8%	$42.5M+14.2%	$37.2M
Accounts Receivable	$686.8M-5.7%	$728.0M+22.2%	$595.7M+15.4%	$516.0M+7.7%	$479.1M-0.4%	$481.1M+2.8%	$468.2M+3.9%	$450.7M
Goodwill	N/A	N/A	N/A	N/A	$5.7M-6.6%	$6.1M+7.0%	$5.7M0.0%	$5.7M
Total Liabilities	$1.4B+9.2%	$1.3B+5.6%	$1.2B+3.8%	$1.2B+2.0%	$1.1B+38.3%	$816.1M+2.6%	$795.8M-26.7%	$1.1B
Current Liabilities	$743.4M+16.5%	$638.0M+16.8%	$546.3M+4.5%	$522.9M+3.0%	$507.7M+18.2%	$429.7M+7.8%	$398.5M-44.1%	$712.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$3.3B+8.3%	$3.0B+11.5%	$2.7B+6.3%	$2.5B-2.1%	$2.6B-4.8%	$2.7B+8.4%	$2.5B+5.2%	$2.4B
Retained Earnings	$447.7M+52.3%	$294.0M+247.9%	$84.5M+1694.3%	-$5.3M-118.2%	$29.2M-64.0%	$81.1M+266.5%	-$48.7M+57.2%	-$113.7M

NBIX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$782.7M+31.5%	$595.4M+52.7%	$389.9M+14.9%	$339.4M+32.3%	$256.5M+12.3%	$228.5M
Capital Expenditures	$34.0M-11.0%	$38.2M+35.0%	$28.3M+71.5%	$16.5M-29.5%	$23.4M+114.7%	$10.9M
Free Cash Flow	$748.7M+34.4%	$557.2M+54.1%	$361.6M+12.0%	$322.9M+38.5%	$233.1M+7.1%	$217.6M
Investing Cash Flow	-$264.4M-108.5%	-$126.8M+72.9%	-$467.1M-163.7%	-$177.1M-36.0%	-$130.2M-3275.6%	$4.1M
Financing Cash Flow	-$38.3M+92.1%	-$486.7M-845.3%	$65.3M+127.9%	-$234.3M-955.1%	$27.4M+117.4%	-$157.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$167.7M-44.1%	$300.0M	$0	$0	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$388.4M+70.7%	$227.5M+123.0%	$102.0M+57.4%	$64.8M-73.3%	$242.5M+53.5%	$158.0M+144.6%	$64.6M-50.4%	$130.3M
Capital Expenditures	-$2.4M-118.2%	$13.2M+5.6%	$12.5M+16.8%	$10.7M+46.6%	$7.3M-9.9%	$8.1M-30.2%	$11.6M+3.6%	$11.2M
Free Cash Flow	$386.0M+80.1%	$214.3M+139.4%	$89.5M+65.4%	$54.1M-77.0%	$235.2M+56.9%	$149.9M+182.8%	$53.0M-55.5%	$119.1M
Investing Cash Flow	-$52.9M+73.1%	-$196.7M-578.3%	-$29.0M-304.2%	$14.2M+120.8%	-$68.3M-376.5%	$24.7M+187.6%	-$28.2M+48.7%	-$55.0M
Financing Cash Flow	$37.3M-18.2%	$45.6M+1481.8%	-$3.3M+97.2%	-$117.9M+59.3%	-$290.0M-1198.5%	$26.4M+109.0%	-$293.0M-519.2%	$69.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$0	$0-100.0%	$17.7M-88.2%	$150.0M-50.0%	$300.0M	$0	$0	$0

NBIX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	98.2%-0.4pp	98.6%+0.7pp	97.9%-0.5pp	98.4%-0.3pp	98.7%-0.3pp	99.0%
Operating Margin	21.6%-2.6pp	24.2%+10.9pp	13.3%-3.4pp	16.7%+7.7pp	9.0%-6.5pp	15.6%
Net Margin	16.7%+2.2pp	14.5%+1.3pp	13.2%+2.8pp	10.4%+2.5pp	7.9%-31.0pp	38.9%
Return on Equity	14.7%+1.5pp	13.2%+2.0pp	11.2%+2.1pp	9.0%+2.5pp	6.5%-29.7pp	36.2%
Return on Assets	10.3%+1.1pp	9.2%+1.5pp	7.7%+1.2pp	6.5%+2.2pp	4.3%-19.2pp	23.5%
Current Ratio	3.390.0	3.40+0.9	2.45-0.2	2.70-1.3	3.96-1.5	5.45
Debt-to-Equity	0.42-0.0	0.44-0.0	0.46+0.1	0.39-0.1	0.51-0.0	0.54
FCF Margin	26.2%+2.5pp	23.7%+4.5pp	19.2%-2.5pp	21.7%+1.1pp	20.6%-0.3pp	20.8%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	97.8%-0.4pp	98.2%-0.1pp	98.4%-0.0pp	98.4%-0.1pp	98.5%-0.2pp	98.7%+0.3pp	98.4%-0.1pp	98.5%
Operating Margin	26.2%-3.9pp	30.1%+8.9pp	21.2%+17.1pp	4.1%-18.5pp	22.6%-6.9pp	29.5%+4.9pp	24.6%+5.4pp	19.3%
Net Margin	19.1%-7.3pp	26.4%+10.7pp	15.6%+14.3pp	1.4%-15.0pp	16.4%-4.4pp	20.9%+9.8pp	11.0%+2.6pp	8.4%
Return on Equity	4.7%-2.3pp	7.0%+3.0pp	4.0%+3.7pp	0.3%-3.7pp	4.0%-0.8pp	4.8%+2.2pp	2.6%+0.8pp	1.8%
Return on Assets	3.3%-1.6pp	4.9%+2.1pp	2.8%+2.5pp	0.2%-2.6pp	2.8%-0.9pp	3.7%+1.7pp	2.0%+0.7pp	1.3%
Current Ratio	3.39+0.0	3.38+0.2	3.20+0.1	3.13-0.3	3.40-1.0	4.37+0.2	4.19+1.7	2.52
Debt-to-Equity	0.420.0	0.42-0.0	0.44-0.0	0.45+0.0	0.44+0.1	0.30-0.0	0.32-0.1	0.46
FCF Margin	47.9%+21.0pp	27.0%+13.9pp	13.0%+3.6pp	9.4%-28.0pp	37.5%+13.4pp	24.1%+15.1pp	9.0%-14.1pp	23.1%

Similar Companies

United Therapeutics Corp. UTHR

$25.0B

Dr Reddys Labs RDY

$11.2B

Viatris Inc Ord Shs VTRS

$15.7B

Teva Pharm TEVA

$35.2B

Takeda Pharm TAK

$59.3B

Frequently Asked Questions

What is Neurocrine Biosciences Inc's annual revenue?

Neurocrine Biosciences Inc (NBIX) reported $2.9B in total revenue for fiscal year 2025. This represents a 21.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Neurocrine Biosciences Inc's revenue growing?

Neurocrine Biosciences Inc (NBIX) revenue grew by 21.4% year-over-year, from $2.4B to $2.9B in fiscal year 2025.

Is Neurocrine Biosciences Inc profitable?

Yes, Neurocrine Biosciences Inc (NBIX) reported a net income of $478.6M in fiscal year 2025, with a net profit margin of 16.7%.

What is Neurocrine Biosciences Inc's EBITDA?

Neurocrine Biosciences Inc (NBIX) had EBITDA of $649.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Neurocrine Biosciences Inc's gross margin?

Neurocrine Biosciences Inc (NBIX) had a gross margin of 98.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Neurocrine Biosciences Inc's operating margin?

Neurocrine Biosciences Inc (NBIX) had an operating margin of 21.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Neurocrine Biosciences Inc's net profit margin?

Neurocrine Biosciences Inc (NBIX) had a net profit margin of 16.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Neurocrine Biosciences Inc's return on equity (ROE)?

Neurocrine Biosciences Inc (NBIX) has a return on equity of 14.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Neurocrine Biosciences Inc's free cash flow?

Neurocrine Biosciences Inc (NBIX) generated $748.7M in free cash flow during fiscal year 2025. This represents a 34.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Neurocrine Biosciences Inc's operating cash flow?

Neurocrine Biosciences Inc (NBIX) generated $782.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Neurocrine Biosciences Inc's total assets?

Neurocrine Biosciences Inc (NBIX) had $4.6B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Neurocrine Biosciences Inc's capital expenditures?

Neurocrine Biosciences Inc (NBIX) invested $34.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Neurocrine Biosciences Inc spend on research and development?

Neurocrine Biosciences Inc (NBIX) invested $1.0B in research and development during fiscal year 2025.

Does Neurocrine Biosciences Inc buy back shares?

Yes, Neurocrine Biosciences Inc (NBIX) spent $167.7M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Neurocrine Biosciences Inc have outstanding?

Neurocrine Biosciences Inc (NBIX) had 100M shares outstanding as of fiscal year 2025.

What is Neurocrine Biosciences Inc's current ratio?

Neurocrine Biosciences Inc (NBIX) had a current ratio of 3.39 as of fiscal year 2025, which is generally considered healthy.

What is Neurocrine Biosciences Inc's debt-to-equity ratio?

Neurocrine Biosciences Inc (NBIX) had a debt-to-equity ratio of 0.42 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Neurocrine Biosciences Inc's return on assets (ROA)?

Neurocrine Biosciences Inc (NBIX) had a return on assets of 10.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Neurocrine Biosciences Inc's Altman Z-Score?

Neurocrine Biosciences Inc (NBIX) has an Altman Z-Score of 7.45, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Neurocrine Biosciences Inc's Piotroski F-Score?

Neurocrine Biosciences Inc (NBIX) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Neurocrine Biosciences Inc's earnings high quality?

Neurocrine Biosciences Inc (NBIX) has an earnings quality ratio of 1.64x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Neurocrine Biosciences Inc?

Neurocrine Biosciences Inc (NBIX) scores 72 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.